Is TMS the Same as Shock Therapy? A Comparison

Transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT), commonly called “shock therapy,” are both brain stimulation treatments for depression, but they work in fundamentally different ways, feel nothing alike for the patient, and carry very different side-effect profiles. The confusion is understandable: both involve sending energy into the brain, and both are used when medication has failed. But grouping them together is a bit like calling an ultrasound the same thing as surgery because both happen in a hospital. The differences matter for anyone weighing treatment options or trying to understand what a doctor has recommended.

How Each Treatment Actually Works

ECT delivers an electrical current directly to the brain while the patient is under general anesthesia. The explicit goal is to trigger a brief, controlled seizure that lasts roughly 30 to 60 seconds. The seizure itself appears to be what drives the therapeutic effect, though the exact reasons why remain an area of active research.¹ Patients are unconscious for the procedure and typically wake up within minutes, though grogginess and confusion can linger for a while afterward.

TMS takes a completely different approach. A magnetic coil placed against the scalp generates a rapidly changing magnetic field that induces a small electrical current in the outer layers of the brain. This current is strong enough to activate neurons in the targeted region but far too weak to cause a seizure under normal conditions.² The stimulation is strongest in the superficial cortex and the white matter just beneath it, and it affects both excitatory and inhibitory nerve fibers in that zone.³ No anesthesia is needed. You sit in a chair, fully awake, and hear a clicking or tapping sound for 20 to 40 minutes per session.

So the core distinction is this: ECT intentionally induces a whole-brain seizure under sedation; TMS magnetically nudges a targeted brain area while you are conscious. Both alter brain activity, but the scale, depth, and invasiveness are worlds apart.

Which One Works Better for Depression

If you are looking purely at remission rates, ECT generally comes out ahead. A meta-analysis pooling data from multiple randomized trials found that ECT achieved a response rate of about 64% and a remission rate of roughly 53%, compared with about 49% response and 32% remission for high-frequency repetitive TMS.⁴ An earlier systematic review found nearly identical numbers, with ECT significantly outperforming high-frequency TMS on both response and remission while showing no real difference in dropout rates between the two treatments.⁵

But here is the part those headline numbers obscure: the gap narrows substantially when you look at specific subgroups. In people with nonpsychotic depression, the same meta-analysis found that high-frequency TMS was roughly as effective as ECT.⁵ ECT’s clear superiority was driven mainly by patients who had psychotic features alongside their depression, a subgroup where ECT has long been considered the strongest option. For the more typical case of treatment-resistant depression without psychosis, the advantage is much less dramatic.

Both treatments reliably reduce depression severity and suicidal thoughts, and head-to-head trials consistently confirm meaningful improvement in both arms.⁶ The practical question for many patients is not whether ECT works better in a statistical sense, but whether the additional efficacy is worth the additional burden of general anesthesia, recovery time, and potential cognitive side effects.

Memory and Thinking After Treatment

This is often the deciding factor for patients choosing between the two, and it is where the treatments differ most starkly. ECT is well known for causing short-term memory disruption. Some people have trouble forming new memories for days to weeks after a treatment course, and a subset report patchy gaps in autobiographical memory that can persist longer. The severity varies depending on the type of electrode placement and the number of sessions, but cognitive side effects are common enough that they are a routine part of the informed-consent conversation before ECT.

TMS, by contrast, does not appear to cause any meaningful memory or cognitive impairment. In a randomized trial that specifically compared short-term cognitive outcomes, the TMS group scored significantly better than the ECT group on multiple tests of attention, processing speed, and executive function at the end of treatment.⁷ That does not mean ECT permanently damages cognition in most people; for many patients, the effects resolve within weeks. But the difference during and immediately after treatment is real and substantial.

How Fast Each Treatment Kicks In

ECT tends to work faster. Registry data comparing the two treatments found that ECT produced more rapid improvement in depression severity, quicker shifts out of the most severe symptom categories, and faster time to treatment response than TMS. ECT also showed greater early reductions in suicidal thinking and greater improvements in overall functioning.⁸ This speed advantage is part of why ECT remains the first-line brain stimulation treatment when someone is acutely suicidal or catatonic: the clinical situation demands the fastest possible relief.

A broader review of evidence on suicide risk supports this picture, finding that ECT rapidly reduces both suicidal thoughts and actual suicide mortality, while TMS appears to lower suicidal thinking primarily through its general antidepressant effect rather than through a separate anti-suicidal mechanism.⁹ When time is the critical variable, ECT has a clear edge.

A typical TMS course runs about four to six weeks of daily sessions (sometimes longer), and many patients do not notice meaningful improvement until several weeks in. ECT courses are usually shorter in total calendar time, often involving two to three sessions per week for three to four weeks, with noticeable changes sometimes appearing after just a few treatments.

What the Treatments Feel Like Day-to-Day

The practical experience of undergoing ECT versus TMS could hardly be more different, and these logistics shape how patients and families perceive each treatment at least as much as the clinical data does.

ECT requires an anesthesia team. You fast before each session, receive general anesthesia and a muscle relaxant, have the seizure induced, and then recover in a monitored setting. You cannot drive yourself home and usually need someone with you for the rest of the day. For working adults, this means significant disruption. The total number of sessions is lower than a TMS course, but each one eats a bigger chunk of time and requires more logistical planning.

TMS requires none of that. You show up, sit in a treatment chair, and leave when it is done. Most people drive themselves to and from sessions and go straight back to work or normal activities. The most common side effects are scalp discomfort at the coil site and a mild headache, both of which tend to fade over the first few sessions. There is no anesthesia hangover, no confusion, and no recovery period.

Surveys of patients who have experienced both treatments reflect this gap. In one study, people who had undergone both TMS and ECT overwhelmingly rated TMS as more acceptable. Almost three-quarters said TMS had been helpful, and the vast majority said they would have TMS again and would recommend it to others.¹⁰ That preference does not mean TMS is the better treatment in every case, but it is a strong signal about lived experience. The gap in acceptability matters because a treatment you are willing to complete and return for is more effective in practice than one you abandon.

Safety Profiles and Who Should Be Cautious

Both treatments are considered safe when administered by trained clinicians, but their risk profiles look quite different. ECT’s main safety concerns revolve around the general anesthesia, the induced seizure, and the cognitive effects already discussed. Serious medical complications from ECT are rare, but the anesthesia carries its own small set of risks, particularly for people with cardiovascular conditions.

TMS side effects are generally milder. Expert safety guidelines note that severe adverse effects like seizures, hearing changes, or manic episodes are uncommon.¹¹ The seizure risk with TMS exists but is estimated at well under 1%, and the safety guidelines specify stimulation thresholds and monitoring protocols designed to keep it that way. Certain groups need extra caution: adolescents, pregnant women, older adults, and anyone with metal or electronic implants in or near the head.¹² People with cochlear implants, deep brain stimulators, or certain types of aneurysm clips are generally excluded from TMS.

Interestingly, ECT is actually considered particularly effective and well-studied in some of the populations where TMS requires special caution, such as older adults and pregnant women with severe depression.¹³ This is partly because ECT has been used for decades longer and has a much deeper evidence base in these groups.

Staying Well After Treatment Ends

Neither ECT nor TMS is a permanent fix. Depression is a condition with high relapse rates, and this remains true regardless of how the initial episode was treated. One study that followed patients for six months after completing either ECT or TMS found that about 20% relapsed in each group, with no significant difference between the two.¹⁴ At the six-month mark, both groups had similarly low depression scores and comparable levels of overall functioning.

For ECT, the standard approach to preventing relapse is “maintenance ECT,” where patients come in for occasional sessions (often monthly) after the acute course ends. Some patients remain on maintenance ECT for years. A small case series explored whether maintenance TMS could serve as a substitute for people who had initially responded to ECT. Over follow-up periods ranging from 7 to 23 months, four out of six patients maintained or improved their clinical status with TMS maintenance, though two eventually relapsed.¹⁵ That is a tiny sample, but it points to TMS maintenance as a potential option for people who want to step down from ECT without losing ground.

For TMS, the lack of established maintenance protocols is a recognized gap. Patients who achieve remission with acute TMS can relapse weeks or months later, and the field has not yet settled on a standard schedule for booster sessions.¹⁶ Many clinics offer tapering schedules or periodic “tune-ups,” but these are based more on clinical judgment than on robust trial data.

What Happens Inside the Brain

Even though both treatments improve depression, they appear to do it through different biological routes. A neuroimaging study that directly compared the two found that ECT induced measurable changes in brain volume in several regions, suggesting structural remodeling or possibly neuroinflammatory effects. TMS did not produce any detectable structural brain changes at the same imaging scale.¹⁷ Both treatments, however, appear to induce functional changes at the circuit level, meaning they alter how brain regions communicate with each other even when only ECT visibly reshapes tissue.

This is an important nuance. ECT’s brain changes are more dramatic, which likely explains both its stronger efficacy in severe cases and its cognitive side effects. TMS works more subtly, modulating the activity of neural circuits without physically altering brain structure. The researchers who conducted the imaging study framed this as evidence that there are “different mechanistic circuit-level therapeutic strategies” for treating depression, even within brain stimulation treatments alone.¹⁷ In other words, these are not two versions of the same thing. They are genuinely different tools that happen to be aimed at the same problem.

Cost and Access

You might assume that TMS, being less invasive, would be cheaper. On a per-session basis it is, because there is no anesthesia team, no operating-room-like setting, and no recovery room. But a standard TMS course involves 30 or more daily sessions, while an ECT course may require only 6 to 12. A cost-effectiveness analysis found that while each TMS session cost less, the total treatment costs over the acute phase were not significantly different between the two. When follow-up care and informal caregiving costs (like time off work for a family member helping with transportation after ECT) were included, the TMS group’s total costs were actually somewhat higher.¹⁸

Insurance coverage varies. In most countries with public health systems, ECT is well established and routinely covered. TMS coverage has expanded significantly in recent years as the evidence base has grown and regulatory approvals have accumulated, but some insurers still require documented failure of multiple medications before approving TMS. Access is also uneven geographically: ECT is available at most major hospitals, while TMS may only be offered at specialized clinics or academic medical centers.

Beyond Depression

Both treatments are being studied for conditions well beyond major depression, though TMS has been explored across a wider range of diagnoses. A comprehensive survey of clinical trials in psychiatric neuromodulation found that while depression accounted for the largest share of trials (about 45%), schizophrenia (18%) and substance use disorders (14%) made up substantial portions as well. More than three-quarters of all neuromodulation trials involved non-convulsive, non-invasive approaches like TMS, reflecting a strong research interest in expanding its applications.¹⁹ TMS has already received regulatory clearance for obsessive-compulsive disorder and smoking cessation in addition to depression, and trials are ongoing for conditions including PTSD, anxiety disorders, and chronic pain.

ECT’s evidence base beyond depression is narrower but deep where it exists. It remains a go-to treatment for acute mania, catatonia, and treatment-resistant schizophrenia, especially when rapid resolution is needed. These are areas where TMS has less established evidence, which is another reason the two treatments are not interchangeable in clinical practice.

Why the “Shock Therapy” Label Sticks to Both

Part of the confusion between TMS and ECT stems from the stigma that has surrounded ECT for decades. When people hear “brain stimulation treatment for depression,” many immediately picture the unmodified ECT scenes from mid-twentieth-century films, where patients were awake, unrestrained, and visibly convulsing. Modern ECT looks nothing like that. Patients are fully anesthetized, muscle relaxants prevent any visible seizure activity, and the procedure is performed in a controlled medical setting with continuous monitoring. But the cultural image persists, and it bleeds over onto newer treatments like TMS by association.

TMS sometimes gets lumped in with “shock therapy” simply because both involve the brain and electricity, even though TMS does not deliver an electrical shock, does not cause a seizure, and does not require anesthesia. For patients considering TMS, the association with ECT can create unnecessary fear. For patients who might benefit from ECT, the stigma can delay or prevent treatment that could be lifesaving, particularly in severe depression with active suicidal ideation where ECT’s faster response time is a genuine clinical advantage.

The two treatments occupy different niches in a psychiatrist’s toolkit. ECT is the heavy-duty option: more effective in the most severe cases, faster-acting, but comes with cognitive trade-offs and logistical complexity. TMS is the lighter-touch approach: well tolerated, easier to fit into daily life, cognitively benign, and roughly comparable to ECT for nonpsychotic depression. Calling TMS “shock therapy” misrepresents both treatments and makes an already difficult decision harder for people who need accurate information to choose well.